News 2017-07-31 16:21 ET - News Release
Mr. Ash Kaushal reports
CHROMEDX WORKS TOWARDS THIRD VERSION OF HEMOPALM PROTOTYPE ANALYZER
ChroMedX Corp. has provided an update on the refinement and testing of the company's HemoPalm system prototype.
The company completed its first HemoPalm system prototype in mid-May in collaboration with rapid prototyping firm Agile Manufacturing Inc. ChroMedX has continued to refine the design and is now in the process of finalizing a third version that addresses key aspects of the size, durability and ergonomics of the device.
"This is a very involved and fast-paced part of the development process. Our third reiteration includes considerable refinements to the usability of the device. Not only will the size of the device decrease, but we will increase durability by optimizing the internal layout of the device's components -- a process made much easier by the accessibility of rapid prototyping," said Ash Kaushal, president and chief executive officer, ChroMedX.
Prototype refinement is overseen by Mr. Kaushal. Rapid prototyping is managed in collaboration with Agile Manufacturing of Uxbridge, Ont., Canada, and continuing refinement of components is managed internally and at the company's Shenzhen-based development partner Hochuen Technologies Co.
U.S. trading
ChroMedX is pleased to announced that earlier this month, the company commenced trading on the OTCQB under the symbol CHXIF. Complete trading details can be found on the OTC markets website.
Website
The company is also pleased to announced the launch of a new website. Investors and individuals interested in keeping abreast of the latest news and updates can subscribe on the home and news pages on the company's website or communicate on the website's contact page.
About ChroMedX Corp.
ChroMedX is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing.
The HemoPalm hand-held blood analyzer system is the only hand-held blood analysis technology, which combines blood gases and electrolytes with full co-oximetry. Currently, this combination is not available on any of the hand-held analyzers on the market. Another competitive advantage of the HemoPalm system will be its ability to draw capillary blood directly from a pinprick site into the cartridge, providing an alternative to arterial blood.
We seek Safe Harbor.